Article
Oncology
Peh Joo Ho, Fuh Yong Wong, Wen Yee Chay, Elaine Hsuen Lim, Zi Lin Lim, Kee Seng Chia, Mikael Hartman, Jingmei Li
Summary: Breast cancer incidence is rising in Asia, but many women in Singapore do not attend routine mammography screening. By utilizing the Gail model and information from the first screen, researchers were able to identify high-risk women and improve the prediction of breast cancer in this population. This risk stratification method has the potential to detect more cancers and benefit women in the long term.
Article
Oncology
Aimilia Gastounioti, Eric A. Cohen, Lauren Pantalone, Sarah Ehsan, Sanjana Vasudevan, Avinash Kurudi, Emily F. Conant, Jinbo Chen, Despina Kontos, Anne Marie McCarthy
Summary: This study aimed to investigate the relationships between mammographic density (MD) and MD change over time and breast cancer risk. The results showed no evidence of an association between short-term MD change and breast cancer risk, suggesting that short-term MD change is not a strong predictor for risk.
BREAST CANCER RESEARCH AND TREATMENT
(2023)
Article
Biochemistry & Molecular Biology
Adam Yala, Peter G. Mikhael, Constance Lehman, Gigin G. Lin, Fredrik Strand, Yung-Liang Wan, Kevin Hughes, Siddharth Satuluru, Thomas Kim, Imon Banerjee, Judy Gichoya, Hari Trivedi, Regina Barzilay
Summary: A reinforcement learning model, Tempo, was introduced to predict risk-based follow-up recommendations in breast cancer screening. The model was trained and validated using large datasets from multiple hospitals. The results showed that Tempo combined with an image-based AI risk model outperformed current clinical practice in terms of simulated early detection. The study demonstrated the potential of AI-based risk models and agile AI-designed screening policies in improving screening programs.
Review
Oncology
Arezo Mokhtary, Andreas Karakatsanis, Antonis Valachis
Summary: The meta-analysis revealed that increasing breast density over time is associated with a higher risk of breast cancer, while decreasing breast density may be linked to a lower risk of breast cancer. This suggests that changes in breast density over time could impact the risk of developing breast cancer.
Article
Computer Science, Artificial Intelligence
Faraz Janan, Michael Brady
Summary: RICE is introduced to enhance contrast and detect focal densities in mammograms, specifically to address cancer masking issues in dense breast categories. Unlike traditional methods, RICE relies on breast tissue composition to highlight focal densities. By segmenting VBD maps and applying a recursive mechanism, RICE enhances the appearance and helps estimate mass density. It can be adapted for use in computer-aided diagnostics and detection systems.
MEDICAL IMAGE ANALYSIS
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Lijuan Shen, Tingting Jiang, Pengzhou Tang, Huijuan Ge, Chao You, Weijun Peng
Summary: Two prediction models were developed based on features of grouped amorphous calcifications, with the ratio model showing superior diagnostic efficiency to the MS model and identifying over 40% of benign biopsies.
QUANTITATIVE IMAGING IN MEDICINE AND SURGERY
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Margarita Posso, Rodrigo Alcantara, Ivonne Vazquez, Laura Comerma, Marisa Bare, Javier Louro, M. Jesus Quintana, Marta Roman, Rafael Marcos-Gragera, Maria Vernet-Tomas, Francina Saladie, Carmen Vidal, Xavier Bargallo, Lupe Penalva, Maria Sala, Xavier Castells
Summary: This study evaluated mammographic features in women with benign breast disease (BBD) and their risk of subsequent breast cancer. Different BBD subtypes showed distinct mammographic findings, with women showing architectural distortion, multiple findings, asymmetries, and calcifications having a higher risk of subsequent breast cancer compared to those with masses.
EUROPEAN RADIOLOGY
(2022)
Article
Oncology
Soyeoun Kim, Boyoung Park
Summary: Breast density changes are associated with breast cancer risk, with an increase in BI-RADS density category between screenings linked to higher breast cancer risk. Longitudinal measures of BI-RADS density may be useful in identifying high-risk women, especially those with a family history of breast cancer.
INTERNATIONAL JOURNAL OF CANCER
(2021)
Article
Oncology
Lijuan Shen, Xiaowen Ma, Tingting Jiang, Xigang Shen, Wentao Yang, Chao You, Weijun Peng
Summary: This study retrospectively analyzed consecutive mammograms and identified potential factors influencing the malignancy risk of amorphous calcifications. A nomogram was developed for malignancy risk stratification based on age, distribution, maximum diameter, and quantity of calcifications. The discrimination performance of the nomogram showed good results in predicting malignant amorphous calcifications.
CANCER MANAGEMENT AND RESEARCH
(2021)
Review
Oncology
Shuangqin Huang, Nehmat Houssami, Meagan Brennan, Brooke Nickel
Summary: Evidence suggests that BDN legislation increases the overall utilization of supplemental screening by 0.5-143%. This effect is amplified if the notification includes a follow-up telephone call informing women about additional screening benefits, and if the state's law mandates insurance cover for supplemental screening. Likelihood of supplemental screening is also influenced by factors such as history of breast biopsy and family history of breast cancer, race, age, socioeconomic status, density category, and physician's specialty and region. Some studies reported increases in biopsy rate (up to 4%) and cancer detection rate (up to 11%) after implementation of BDN legislation.
BREAST CANCER RESEARCH AND TREATMENT
(2021)
Article
Oncology
Soyeoun Kim, Thi Xuan Mai Tran, Huiyeon Song, Boyoung Park
Summary: Breast density and microcalcifications are associated with breast cancer risk. The study shows that microcalcification is an independent risk factor for breast cancer, and its risk is elevated when combined with breast density.
BREAST CANCER RESEARCH
(2022)
Article
Medicine, General & Internal
Gaurav J. Bansal, Lauren Emanuel, Sesha Kanagasabai
Summary: Multiple clusters, linear/segmental distribution, pleomorphic morphology, size of mammographic microcalcifications, and increasing age were independent predictors of malignancy. Patients with previous breast biopsies had a lower risk of breast malignancy.
POSTGRADUATE MEDICAL JOURNAL
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Brian N. Dontchos, Adam Yala, Regina Barzilay, Justin Xiang, Constance D. Lehman
Summary: The study aimed to externally validate a deep learning model in a community breast imaging practice, with results showing high clinical acceptance of the model's density prediction among both academic and community radiologists.
ACADEMIC RADIOLOGY
(2021)
Review
Radiology, Nuclear Medicine & Medical Imaging
Leslie Pereira, Marcella T. Ferreira, Antonio Gilcler F. Lima, Camila Salata, Samara C. Ferreira-Machado, I Lima, Veronica Morandi, Luis A. G. Magalhaes
Summary: The study investigated the biological effects of low doses of mammography on mammary cells in vitro, finding different responses to apoptosis among cell lines and an increase in DSBs in tumor cell lines. While the health benefits of early breast screening are clear, further research is needed to explore the effects of low-dose radiation on breast cells and potential risks in repeated mammography screening.
PHYSICA MEDICA-EUROPEAN JOURNAL OF MEDICAL PHYSICS
(2021)
Editorial Material
Biochemistry & Molecular Biology
Nehmat Houssami, Karla Kerlikowske
Summary: AI has the potential to be a new tool in the risk assessment and screening of breast cancer, but its impact on relevant clinical outcomes needs to be prospectively evaluated.
Article
Oncology
Parvin F. Peddi, Peter A. Fasching, Duan Liu, Emmanuel Quinaux, Nicholas J. Robert, Vicente Valero, John Crown, Carla Falkson, Adam Brufsky, Julie M. Cunningham, Richard M. Weinshilboum, Tadeusz Pienkowski, Wolfgang Eiermann, Miguel Martin, Valerie Bee, Xiaoyan Wang, Liewei Wang, Eric Yang, Dennis J. Slamon, Sara A. Hurvitz
Summary: This study investigated the association between genetic polymorphisms and disease-free survival and cardiac toxicity in HER2-positive breast cancer patients treated with trastuzumab and/or anthracyclines. The results showed no correlation between the studied polymorphisms and disease-free survival or cardiac toxicity.
CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
Ashley Weir, Eun-Young Kang, Nicola S. Meagher, Gregg S. Nelson, Prafull Ghatage, Cheng-Han Lee, Marjorie J. Riggan, Aleksandra Gentry-Maharaj, Andy Ryan, Naveena Singh, Martin Widschwendter, Jennifer Alsop, Michael S. Anglesio, Matthias W. Beckmann, Jessica Berger, Christiani Bisinotto, Jessica Boros, Alison H. Brand, James D. Brenton, Angela Brooks-Wilson, Michael E. Carney, Julie M. Cunningham, Kara L. Cushing-Haugen, Cezary Cybulski, Esther Elishaev, Ramona Erber, Sian Fereday, Anna Fischer, Luis Paz-Ares, Javier Gayarre, Blake C. Gilks, Marcel Grube, Paul R. Harnett, Holly R. Harris, Arndt Hartmann, Alexander Hein, Joy Hendley, Brenda Y. Hernandez, Sabine Heublein, Yajue Huang, Tomasz Huzarski, Anna Jakubowska, Mercedes Jimenez-Linan, Catherine J. Kennedy, Felix K. F. Kommoss, Jennifer M. Koziak, Bernhard Kraemer, Nhu D. Le, Jaime Lesnock, Jenny Lester, Jan Lubinski, Janusz Menkiszak, Britta Ney, Alexander Olawaiye, Sandra Orsulic, Ana Osorio, Luis Robles-Diaz, Matthias Ruebner, Mitul Shah, Raghwa Sharma, Yurii B. Shvetsov, Helen Steed, Aline Talhouk, Sarah E. Taylor, Nadia Traficante, Robert A. Vierkant, Chen Wang, Lynne R. Wilkens, Stacey J. Winham, Javier Benitez, Andrew Berchuck, David D. Bowtell, Francisco J. Candido dos Reis, Linda S. Cook, Anna DeFazio, Jennifer A. Doherty, Peter A. Fasching, Maria J. Garcia, Ellen L. Goode, Marc T. Goodman, Jacek Gronwald, David G. Huntsman, Beth Y. Karlan, Stefan Kommoss, Francesmary Modugno, Joellen M. Schildkraut, Hans-Peter Sinn, Annette Staebler, Linda E. Kelemen, Caroline E. Ford, Usha Menon, Paul D. P. Pharoah, Martin Koebel, Susan J. Ramus, D. Bowtell, A. DeFazio, N. Traficante, S. Fereday, A. Brand, P. Harnett, R. Sharma
Summary: Recently, a study found a positive correlation between protein expression of FOXJ1 and the 5-year survival rate of patients with tubo-ovarian high-grade serous carcinoma (HGSC). However, protein expression of GMNN was not significantly associated with patient survival. This study provides preliminary evidence for the prognostic value of FOXJ1 in HGSC and validates the prior mRNA-based prognostic association through immunohistochemistry.
BRITISH JOURNAL OF CANCER
(2023)
Article
Psychology, Developmental
Melanie Kungl, Pascal Vrticka, Christine Heinisch, Matthias W. Beckmann, Peter A. Fasching, Clara Ziegler, Gottfried Spangler
Summary: Neurophysiological evidence suggests a link between attachment and the neural processing of emotion expressions. This study examines this relationship in middle childhood and investigates the impact of facial familiarity. The results show that attachment deactivation is associated with increased vigilance towards angry faces, while no effect of hyperactivation is found.
ATTACHMENT & HUMAN DEVELOPMENT
(2023)
Article
Medicine, Research & Experimental
Min Huang, Peter A. Fasching, Amin Haiderali, Weiguang Xue, Chelsey Yang, Wilbur Pan, Zheng-Yi Zhou, Peter Hu, Mitashri Chaudhuri, Celine Le Bailly De Tilleghem, Nicolas Cappoen, Joyce O'Shaughnessy
Summary: This study evaluated the cost-effectiveness of adding pembrolizumab to neoadjuvant chemotherapy and continuing it as a single-agent adjuvant treatment for high-risk eTNBC in the USA. The results showed that pembrolizumab in combination with chemotherapy is a cost-effective option for these patients.
ADVANCES IN THERAPY
(2023)
Article
Oncology
Hanna Huebner, Matthias Ruebner, Christian Kurbacher, Peyman Hadji, Andreas D. Hartkopf, Michael P. Lux, Jens Huober, Sabrina Uhrig, Florin-Andrei Taran, Friedrich Overkamp, Hans Tesch, Lothar Haeberle, Diana Lueftner, Markus Wallwiener, Volkmar Mueller, Matthias W. Beckmann, Alexander Hein, Erik Belleville, Michael Untch, Wolfgang Janni, Tanja N. Fehm, Hans-Christian Kolberg, Diethelm Wallwiener, Sara Y. Brucker, Andreas Schneeweiss, Johannes Ettl, Peter A. Fasching, Laura L. Michel
Summary: The PRAEGNANT study is a registry study that analyzed genetic alterations in 37 breast cancer predisposition genes for 396 metastatic breast cancer patients. The study aimed to return genetic results to physicians and evaluate the impact on treatment decisions and patients' quality of life. Evaluation of the study scored 7 out of 10.
BREAST CANCER RESEARCH AND TREATMENT
(2023)
Article
Oncology
Eun-Young Kang, Ashley Weir, Nicola S. Meagher, Kyo Farrington, Gregg S. Nelson, Prafull Ghatage, Cheng-Han Lee, Marjorie J. Riggan, Adelyn Bolithon, Gordana Popovic, Betty Leung, Katrina Tang, Neil Lambie, Joshua Millstein, Jennifer Alsop, Michael S. Anglesio, Beyhan Ataseven, Ellen Barlow, Matthias W. Beckmann, Jessica Berger, Christiani Bisinotto, Hans Boesmueller, Jessica Boros, Alison H. Brand, Angela Brooks-Wilson, Sara Y. Brucker, Michael E. Carney, Yovanni Casablanca, Alicia Cazorla-Jimenez, Paul A. Cohen, Thomas P. Conrads, Linda S. Cook, Penny Coulson, Madeleine Courtney-Brooks, Daniel W. Cramer, Philip Crowe, Julie M. Cunningham, Cezary Cybulski, Kathleen M. Darcy, Mona A. El-Bahrawy, Esther Elishaev, Ramona Erber, Rhonda Farrell, Sian Fereday, Anna Fischer, Maria J. Garcia, Simon A. Gayther, Aleksandra Gentry-Maharaj, C. Blake Gilks, Marcel Grube, Paul R. Harnett, Shariska Petersen Harrington, Philipp Harter, Arndt Hartmann, Jonathan L. Hecht, Sebastian Heikaus, Alexander Hein, Florian Heitz, Joy Hendley, Brenda Y. Hernandez, Susanna Hernando Polo, Sabine Heublein, Akira Hirasawa, Estrid Hogdall, Claus K. Hogdall, Hugo M. Horlings, David G. Huntsman, Tomasz Huzarski, Andrea Jewell, Mercedes Jimenez-Linan, Michael E. Jones, Scott H. Kaufmann, Catherine J. Kennedy, Dineo Khabele, Felix K. F. Kommoss, Roy F. P. M. Kruitwagen, Diether Lambrechts, Nhu D. Le, Marcin Lener, Jenny Lester, Yee Leung, Anna Linder, Liselore Loverix, Jan Lubinski, Rashna Madan, G. Larry Maxwell, Francesmary Modugno, Susan L. Neuhausen, Alexander Olawaiye, Siel Olbrecht, Sandra Orsulic, Jose Palacios, Celeste Leigh Pearce, Malcolm C. Pike, Carmel M. Quinn, Ganendra Raj Mohan, Cristina Rodriguez-Antona, Matthias Ruebner, Andy Ryan, Stuart G. Salfinger, Naoko Sasamoto, Joellen M. Schildkraut, Minouk J. Schoemaker, Mitul Shah, Raghwa Sharma, Yurii B. Shvetsov, Naveena Singh, Gabe S. Sonke, Linda Steele, Colin J. R. Stewart, Karin Sundfeldt, Anthony J. Swerdlow, Aline Talhouk, Adeline Tan, Sarah E. Taylor, Kathryn L. Terry, Aleksandra Toloczko, Nadia Traficante, Koen K. Van de Vijver, Maaike A. van der Aa, Toon Van Gorp, Els Van Nieuwenhuysen, Lilian Van-Wagensveld, Ignace Vergote, Robert A. Vierkant, Chen Wang, Lynne R. Wilkens, Stacey J. Winham, Anna H. Wu, Javier Benitez, Andrew Berchuck, Francisco J. Candido Dos Reis, Anna DeFazio, Peter A. Fasching, Ellen L. Goode, Marc T. Goodman, Jacek Gronwald, Beth Y. Karlan, Stefan Kommoss, Usha Menon, Hans-Peter Sinn, Annette Staebler, James D. Brenton, David D. Bowtell, Paul D. P. Pharoah, Susan J. Ramus, Martin Kobel
Summary: This study validates that high-level amplification of CCNE1 is associated with shorter survival in tubo-ovarian high-grade serous carcinoma (HGSC), supporting its use as a prognostic biomarker in this disease.
Article
Oncology
Peter A. Fasching, Alexander Hein, Hans-Christian Kolberg, Lothar Haeberle, Sabrina Uhrig, Matthias Ruebner, Erik Belleville, Carolin C. Hack, Tanja N. Fehm, Wolfang Janni, Arndt Hartmann, Ramona Erber, Anna-Katharin Theuser, Sara Y. Brucker, Andreas D. Hartkopf, Michael Untch
Summary: This study investigated the efficacy of nP-containing neoadjuvant chemotherapy in combination with pembrolizumab for breast cancer patients. The results showed a high pathological complete response rate and acceptable side effects.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Biochemistry & Molecular Biology
Gisella Figlioli, Amandine Billaud, Thomas U. Ahearn, Natalia N. Antonenkova, Heiko Becher, Matthias W. Beckmann, Sabine Behrens, Javier Benitez, Marina Bermisheva, Marinus J. Blok, Natalia Bogdanova, Bernardo Bonanni, Barbara Burwinkel, Nicola J. Camp, Archie Campbell, Jose E. Castelao, Melissa H. Cessna, Stephen J. Chanock, Kamila Czene, Peter Devilee, Thilo Doerk, Christoph Engel, Mikael Eriksson, Peter A. Fasching, Jonine D. Figueroa, Marike Gabrielson, Manuela Gago-Dominguez, Montserrat Garcia-Closas, Anna Gonzalez-Neira, Felix Grassmann, Pascal Guenel, Melanie Gundert, Andreas Hadjisavvas, Eric Hahnen, Per Hall, Ute Hamann, Patricia A. Harrington, Wei He, Peter Hillemanns, Antoinette Hollestelle, Maartje J. Hooning, Reiner Hoppe, Anthony Howell, Keith Humphreys, Agnes Jager, Anna Jakubowska, Elza K. Khusnutdinova, Yon-Dschun Ko, Vessela N. Kristensen, Annika Lindblom, Jolanta Lissowska, Jan Lubinski, Arto Mannermaa, Siranoush Manoukian, Sara Margolin, Dimitrios Mavroudis, William G. Newman, Nadia Obi, Mihalis Panayiotidis, Muhammad U. Rashid, Valerie Rhenius, Matti A. Rookus, Emmanouil Saloustros, Elinor J. Sawyer, Rita K. Schmutzler, Mitul Shah, Reijo Sironen, Melissa C. Southey, Maija Suvanto, Rob A. E. M. Tollenaar, Ian Tomlinson, Therese Truong, Lizet E. van der Kolk, Elke M. van Veen, Barbara Wappenschmidt, Xiaohong R. Yang, Manjeet K. Bolla, Joe Dennis, Alison M. Dunning, Douglas F. Easton, Michael Lush, Kyriaki Michailidou, Paul D. P. Pharoah, Qin Wang, Muriel A. Adank, Marjanka K. Schmidt, Irene L. Andrulis, Jenny Chang-Claude, Heli Nevanlinna, Georgia Chenevix-Trench, D. Gareth Evans, Roger L. Milne, Paolo Radice, Paolo Peterlongo
Summary: Evidence from the BRIDGES study suggests that germline protein truncating variants (PTVs) in FANCM are associated with increased risk of ER-negative and triple-negative breast cancer (TNBC), particularly for those with a family history. This study further investigates the association between FANCM missense variants (MVs) and breast cancer risk using the BRIDGES study, analyzing a total of 689 MVs. The results indicate that FANCM MVs may be low/moderate risk factors for ER-negative and TNBC subtypes of breast cancer.
EUROPEAN JOURNAL OF HUMAN GENETICS
(2023)
Article
Oncology
Hope S. Rugo, Seock-Ah Im, Fatima Cardoso, Javier Cortes, Giuseppe Curigliano, Antonino Musolino, Mark D. Pegram, Thomas Bachelot, Gail S. Wright, Cristina Saura, Santiago Escriva-de-Romani, Michelino De Laurentiis, Gary N. Schwartz, Timothy J. Pluard, Francesco Ricci, William R. Gwin II, Christelle Levy, Ursa Brown-Glaberman, Jean-Marc Ferrero, Maaike de Boer, Sung-Bae Kim, Katarina Petrakova, Denise A. Yardley, Orit Freedman, Erik H. Jakobsen, Einav Nili Gal-Yam, Rinat Yerushalmi, Peter A. Fasching, Peter A. Kaufman, Emily J. Ashley, Raul Perez-Olle, Shengyan Hong, Minori Koshiji Rosales, William J. Gradishar
Summary: Clinical trials often report initial results based on the primary end point, while additional results from secondary analyses may not be available. In this study comparing margetuximab and trastuzumab in breast cancer patients, the final overall survival analysis did not show an advantage of margetuximab over trastuzumab. However, exploratory analysis suggested potential improvements in specific patient groups based on CD16A genotyping.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Zhuxuan Fu, Maria Mori Brooks, Sarah Irvin, Susan Jordan, Katja K. H. Aben, Hoda Anton-Culver, Elisa Bandera, Matthias W. Beckmann, Andrew Berchuck, Angela Brooks-Wilson, Jenny Chang-Claude, Linda S. Cook, Daniel W. Cramer, Kara L. Cushing-Haugen, Jennifer A. Doherty, Arif B. Ekici, Peter A. Fasching, Renee T. Fortner, Simon A. Gayther, Aleksandra Gentry-Maharaj, Graham G. Giles, Ellen L. Goode, Marc T. Goodman, Holly R. Harris, Alexander Hein, Rudolf Kaaks, Lambertus A. Kiemeney, Martin Koebel, Joanne Kotsopoulos, Nhu D. Le, Alice W. Lee, Keitaro Matsuo, Valerie McGuire, John R. McLaughlin, Usha Menon, Roger L. Milne, Kirsten B. Moysich, Celeste Leigh Pearce, Malcolm C. Pike, Bo Qin, Susan J. Ramus, Marjorie J. Riggan, Joseph H. Rothstein, Joellen M. Schildkraut, Weiva Sieh, Rebecca Sutphen, Kathryn L. Terry, Pamela J. Thompson, Linda Titus, Anne M. van Altena, Emily White, Alice S. Whittemore, Anna H. Wu, Wei Zheng, Argyrios Ziogas, Sarah E. Taylor, Lu Tang, Thomas Songer, Nicolas Wentzensen, Penelope M. Webb, Harvey A. Risch, Francesmary Modugno
Summary: The lifetime ovulatory years (LOY) are positively associated with nonmucinous epithelial ovarian cancer (EOC) risk, implicating factors beyond ovulation in the development of EOC. The protective effects of parity and oral contraceptive use may not solely depend on anovulation.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
(2023)
Article
Genetics & Heredity
Stefanie H. Mueller, Alvina G. Lai, Maria Valkovskaya, Kyriaki Michailidou, Manjeet K. Bolla, Qin Wang, Joe Dennis, Michael Lush, Zomoruda Abu-Ful, Thomas U. Ahearn, Irene L. Andrulis, Hoda Anton-Culver, Natalia N. Antonenkova, Volker Arndt, Kristan J. Aronson, Annelie Augustinsson, Thais Baert, Laura E. Beane Freeman, Matthias W. Beckmann, Sabine Behrens, Javier Benitez, Marina Bermisheva, Carl Blomqvist, Natalia Bogdanova, Stig E. Bojesen, Bernardo Bonanni, Hermann Brenner, Sara Y. Brucker, Saundra S. Buys, Jose E. Castelao, Tsun L. Chan, Jenny Chang-Claude, Stephen J. Chanock, Ji-Yeob Choi, Wendy K. Chung, Sarah Colonna, Sten Cornelissen, Fergus J. Couch, Kamila Czene, Mary B. Daly, Peter Devilee, Thilo Dork, Laure Dossus, Miriam Dwek, Diana M. Eccles, Arif B. Ekici, A. Heather Eliassen, Christoph Engel, D. Gareth Evans, Peter A. Fasching, Olivia Fletcher, Henrik Flyger, Manuela Gago-Dominguez, Yu-Tang Gao, Montserrat Garcia-Closas, Jose A. Garcia-Saenz, Jeanine Genkinger, Aleksandra Gentry-Maharaj, Felix Grassmann, Pascal Guenel, Melanie Gundert, Lothar Haeberle, Eric Hahnen, Christopher A. Haiman, Niclas Hakansson, Per Hall, Elaine F. Harkness, Patricia A. Harrington, Jaana M. Hartikainen, Mikael Hartman, Alexander Hein, Weang-Kee Ho, Maartje J. Hooning, Reiner Hoppe, John L. Hopper, Richard S. Houlston, Anthony Howell, David J. Hunter, Dezheng Huo, Abctb Investigators, Hidemi Ito, Motoki Iwasaki, Anna Jakubowska, Wolfgang Janni, Esther M. John, Michael E. Jones, Audrey Jung, Rudolf Kaaks, Daehee Kang, Elza K. Khusnutdinova, Sung-Won Kim, Cari M. Kitahara, Stella Koutros, Peter Kraft, Vessela N. Kristensen, Katerina Kubelka-Sabit, Allison W. Kurian, Ava Kwong, James Lacey, Diether Lambrechts, Loic Le Marchand, Jingmei Li, Martha Linet, Wing-Yee Lo, Jirong Long, Artitaya Lophatananon, Arto Mannermaa, Mehdi Manoochehri, Sara Margolin, Keitaro Matsuo, Dimitrios Mavroudis, Usha Menon, Kenneth Muir, Rachel A. Murphy, Heli Nevanlinna, William G. Newman, Dieter Niederacher, Katie M. O'Brien, Nadia Obi, Kenneth Offit, Olufunmilayo Olopade, Andrew F. Olshan, Hakan Olsson, Sue K. Park, Alpa Patel, Achal Patel, Charles M. Perou, Julian Peto, Paul D. P. Pharoah, Dijana Plaseska-Karanfilska, Nadege Presneau, Brigitte Rack, Paolo Radice, Dhanya Ramachandran, Muhammad U. Rashid, Gad Rennert, Atocha Romero, Kathryn J. Ruddy, Matthias Ruebner, Emmanouil Saloustros, Dale P. Sandler, Elinor J. Sawyer, Marjanka K. Schmidt, Rita K. Schmutzler, Michael O. Schneider, Christopher Scott, Mitul Shah, Priyanka Sharma, Chen-Yang Shen, Xiao-Ou Shu, Jacques Simard, Harald Surowy, Rulla M. Tamimi, William J. Tapper, Jack A. Taylor, Soo Hwang Teo, Lauren R. Teras, Amanda E. Toland, Rob A. E. M. Tollenaar, Diana Torres, Gabriela Torres-Mejia, Melissa A. Troester, Therese Truong, Celine M. Vachon, Joseph Vijai, Clarice R. Weinberg, Camilla Wendt, Robert Winqvist, Alicja Wolk, Anna H. Wu, Taiki Yamaji, Xiaohong R. Yang, Jyh-Cherng Yu, Wei Zheng, Argyrios Ziogas, Elad Ziv, Alison M. Dunning, Douglas F. Easton, Harry Hemingway, Ute Hamann, Karoline B. Kuchenbaecker
Summary: This study identified 14 genes associated with breast cancer using gene-based aggregation analysis, including two newly discovered genes FMNL3 and AC058822.1. Furthermore, associations with established candidate genes like ESR1 were found through the collaboration of multi-ancestral cohorts, highlighting the importance of diversifying study cohorts. These findings provide new insights into the development of breast cancer.
Article
Medicine, General & Internal
Carla E. Schulmeyer, Peter A. Fasching, Lothar Haeberle, Julia Meyer, Michael Schneider, David Wachter, Matthias Ruebner, Patrik Poeschke, Matthias W. Beckmann, Arndt Hartmann, Ramona Erber, Paul Gass
Summary: The study evaluated the prognosis of patients with triple-negative breast cancer (TNBC) and other subtypes by using a biomarker panel including cytokeratin 5 (CK5), cluster of differentiation 117 (CD117), and epidermal growth factor receptor (EGFR). The results showed that the non-TBN subgroup of TNBC lesions with at least one positive biomarker (CK5, CD117, and/or EGFR) had longer disease-free survival (DFS) and overall survival (OS). This highlights the importance of molecular-based subclassifications of breast cancer for treatment options and prognosis stratification.
Article
Oncology
Raphela A. Ranjan, Julienne K. Muenzner, Philipp Kunze, Carol I. Geppert, Matthias Ruebner, Hanna Huebner, Peter A. Fasching, Matthias W. Beckmann, Tobias Baeuerle, Arndt Hartmann, Wolfgang Walther, Markus Eckstein, Ramona Erber, Regine Schneider-Stock
Summary: The biological and growth characteristics of two breast cancer cell lines were investigated in a CAM model, and the results confirmed the known features of the breast cancer cell lines observed in vitro and in cells. The CAM model was found to be a reliable alternative for breast cancer research, reducing the need for murine animal experiments.
Article
Obstetrics & Gynecology
Michael O. Schneider, Jutta Pretscher, Tamme W. Goecke, Lothar Haeberle, Anne Engel, Johannes Kornhuber, Anna Eichler, Arif B. Ekici, Matthias W. Beckmann, Peter A. Fasching, Eva Schwenke
Summary: This study did not find any association between the candidate haplotypes analyzed in PGR and CYP19A1 genes, as well as single SNPs in ESR1 and COMT genes, with depression scores assessed by EPDS in a cohort of healthy unselected pregnant women.
ARCHIVES OF GYNECOLOGY AND OBSTETRICS
(2023)
Meeting Abstract
Oncology
Carsten Denkert, Andreas Schneeweiss, Julia Rey, Thomas Karn, Michael Braun, Jens Bodo Huober, Hans-Peter Sinn, Dirk Michael Zahm, Claus Hanusch, Frederik Marme, Jenny Furlanetto, Joerg Thomalla, Jens U. Blohmer, Marion Van Mackelenbergh, Peter Staib, Christian Jackisch, Peter A. Fasching, Bruno Valentin Sinn, Michael Untch, Sibylle Loibl
JOURNAL OF CLINICAL ONCOLOGY
(2022)